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Race and Ethnicity, Obesity, Metabolic Health, and Risk of
Cardiovascular Disease in Postmenopausal Women
Michelle D. Schmiegelow, MD; Haley Hedlin, PhD; Rachel H. Mackey, PhD, MPH; Lisa W. Martin, MD; Mara Z. Vitolins, DrPH;
Marcia L. Stefanick, PhD; Marco V. Perez, MD; Matthew Allison, MD, MPH; Mark A. Hlatky, MD
Background-—It is unclear whether obesity unaccompanied by metabolic abnormalities is associated with increased cardiovascular
disease risk across racial and ethnic subgroups.
Methods and Results-—We identified 14 364 postmenopausal women from the Women’s Health Initiative who had data on fasting
serum lipids and serum glucose and no history of cardiovascular disease or diabetes at baseline. We categorized women by body
mass index (in kg/m2) as normal weight (body mass index 18.5 to <25), overweight (body mass index 25 to <30), or obese (body
mass index ≥30) and by metabolic health, defined first as the metabolic syndrome (metabolically unhealthy: ≥3 metabolic
abnormalities) and second as the number of metabolic abnormalities. We used Cox proportional hazards regression to assess
associations between baseline characteristics and cardiovascular risk. Over 13 years of follow-up, 1101 women had a first
cardiovascular disease event (coronary heart disease or ischemic stroke). Among black women without metabolic syndrome,
overweight women had higher adjusted cardiovascular risk than normal weight women (hazard ratio [HR] 1.49), whereas among white
women without metabolic syndrome, overweight women had similar risk to normal weight women (HR 0.92, interaction P=0.05).
Obese black women without metabolic syndrome had higher adjusted risk (HR 1.95) than obese white women (HR 1.07; interaction
P=0.02). Among women with only 2 metabolic abnormalities, cardiovascular risk was increased in black women who were overweight
(HR 1.77) or obese (HR 2.17) but not in white women who were overweight (HR 0.98) or obese (HR 1.06). Overweight and obese
women with ≤1 metabolic abnormality did not have increased cardiovascular risk, regardless of race or ethnicity.
Conclusions-—Metabolic abnormalities appeared to convey more cardiovascular risk among black women. ( J Am Heart Assoc.
2015;4:e001695 doi: 10.1161/JAHA.114.001695)
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O besity has become a worldwide epidemic,
1 so methods
to identify those at risk of obesity-related cardiovas-
cular disease (CVD) morbidity and mortality are warranted.
The excess cardiovascular risk of obese persons may be
attributable primarily to metabolic mediators rather than to
obesity per se,2,3 and insulin resistance has been suggested
as a key pathophysiological link between obesity and
cardiovascular risk.4 Some persons appear to be “metabol-
ically healthy obese,”5,6 in that they are not insulin resistant
and lack most of the metabolic abnormalities composing the
metabolic syndrome.7 In white populations, the cardiovas-
cular risk of the metabolically healthy obese group appears
to be no higher than that of metabolically healthy persons of
normal weight.5,8,9 In other racial and ethnic groups,
however, the cardiovascular risk among metabolically
healthy obese persons is largely unexplored, and may differ
from that among white persons; not only does the preva-
lence of cardiovascular risk factors differ across race and
ethnicity, but some risk factors, such as hypertension,
appear to be associated with a higher cardiovascular risk in
black persons.10,11
We aimed to characterize cardiovascular risk according to
obesity level and metabolic health status across racial and
ethnic subgroups. In identification of persons with elevated
cardiovascular risk in relation to obesity, we also sought to
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investigate whether the standard definition of metabolically
healthy obese applied to the various racial and ethnic
subgroups by quantifying the number and the type of
metabolic syndrome components.
Methods
Study Population
The Women’s Health Initiative (WHI) recruited a large
multiethnic cohort of postmenopausal women aged 50 to
79 years at baseline throughout the United States during
1993–1998. The WHI consisted of an observational study
cohort and 3 clinical trial cohorts (a diet modification trial, a
menopausal hormone therapy trial, and/or a calcium/vitamin
D trial) that defined and measured clinical variables uniformly
across all studies. The scientific rationale, study design,
eligibility criteria, and baseline characteristics of these studies
have been reported.12–15 The WHI studies were approved by
institutional review committees at each participating center,
and all participants gave written informed consent. The
present study included women from 2 biomarker subcohorts
of the WHI and its Extension Study (2005–2010): the SNP
Health Association Resource cohort (n=11 967), which com-
prised black and Hispanic participants from either the
observational trial or the clinical trial cohorts, and the
European American Hormone Trial subcohort (n=10 161),
which primarily comprised white women from the menopausal
hormone therapy trials.
The WHI excluded women with predicted survival of
<3 years and women with alcohol or drug dependency or
mental illness; the clinical trials also excluded women with
any invasive cancer in the previous 10 years, hepatitis or
cirrhosis, or blood pressure ≥200/105 mm Hg; and the
menopausal hormone therapy trials also excluded women
with a history of pulmonary embolus, deep venous thrombo-
embolism, or hypertriglyceridemia. For the present study, we
excluded women with prior CVD, defined as a previous history
of myocardial infarction, stroke, cardiac catheterization,
percutaneous coronary intervention, coronary artery bypass
surgery, heart failure, atrial fibrillation, or aortic aneurysm at
entry, or with prior diabetes, defined as a self-reported
medical history of diabetes, treatment with glucose-lowering
agents, or a fasting serum glucose level ≥126 mg/dL
(≥7.0 mmol/L). Because of insufficient data for analysis, we
also excluded women with missing data on pertinent variables
(height, weight, waist circumference, age, smoking, systolic or
diastolic blood pressure, treatment for hypertension, triglyce-
rides, high-density lipoprotein cholesterol [HDL-C], fasting
serum glucose, baseline hormone use, or any of the exclusion
variables), women who provided data only at baseline, and
women who were underweight (body mass index [BMI; in kg/
m2] <18.5). Race or ethnicity was categorized as non-Hispanic
white women (hereafter referred to as white women), non-
Hispanic black women (hereafter referred to as black women),
and Hispanic women.
Exposure Definitions
During the baseline clinic visit, each study participant
completed self-administered questionnaires on medical his-
tory, smoking, diet, physical activity, and other lifestyle-
related factors and had blood pressure, weight, and height
measured. Waist circumference was measured to nearest
0.5 cm at the narrowest part of the torso at the end of a
normal expiration. Women in the biomarker studies had
blood samples drawn after a 12-hour fast. Glucose was
analyzed using the Gluco-quant glucose/hexokinase reagent
(Roche), triglycerides were analyzed using the Triglyceride
GB reagent (Roche), and HDL-C was analyzed using the HDL-
C Plus third-generation direct method (Roche), all on a
Roche Modular P chemistry analyzer. All assays for the
biomarker studies were done on serum by the University of
Minnesota Medical Center laboratory, and average assay
correlation variances were 2% for glucose, 2% for triglyce-
rides, and 3% for HDL-C.
We defined the metabolic abnormalities composing the
metabolic syndrome according to the 2009 joint interim
statement of the International Diabetes Federation and the
American Heart Association/National Heart, Lung, and Blood
Institute,7 based on increased waist circumference ≥80 cm,
increased level of triglycerides ≥150 mg/dL (≥1.7 mmol/L),
decreased level of HDL-C <50 mg/dL (<1.3 mmol/L),
increased blood pressure with either systolic blood pressure
≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or
treatment with antihypertensive drugs, and impaired fasting
serum glucose ≥100 mg/dL (5.6 mmol/L). Consistent with
other studies, we defined metabolically unhealthy as the
presence of ≥3 metabolic abnormalities (metabolic syndrome)
and metabolically healthy as ≤2 metabolic abnormalities.16
Primary End Point
The primary outcome was time to first CVD event defined as
nonfatal and fatal coronary heart disease or ischemic stroke,
identified using annual mailed questionnaires (semiannual for
clinical trials, response rates >95%) and adjudicated locally
and centrally by physicians blinded to exposure data by use of
medical records and standard criteria.17 Standardized criteria
for electrocardiographic changes, elevated cardiac enzymes,
or both were used to define nonfatal myocardial infarction. A
diagnosis of ischemic stroke required a hospital admission
with rapid onset of neurological deficit persisting >24 hours,
attributed to occlusion of cerebral or extracranial arteries with
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infarction and without evidence of other cause. Fatal events
were confirmed by documentation in hospital, by autopsy
reports, or both. The participants were followed until Decem-
ber 31, 2010, or until first CVD event, loss to follow-up, death
from any cause, or last visit prior to the end of Extension
Study I at December 31, 2010, whichever came first.
Statistical Methods
We categorized the study population by metabolic health
status within each BMI category: normal weight (18.5 to
<25.0), overweight (25.0 to <30.0), or obese (BMI ≥30.0).
We assessed the associations between obesity and
metabolic subtypes and the risk of CVD by use of multivar-
iable Cox proportional hazards regression. Because the aim of
the study was to examine the race-specific cardiovascular risk
according to obesity and metabolic health subtypes, analyses
were performed separately by race or ethnicity (white, black,
Hispanic). Normal weight women with <3 (0, 1, or 2)
metabolic abnormalities were used as a reference category
in all analyses unless otherwise stated. Metabolic abnormal-
ities were categorized using 3 different approaches. First,
metabolic abnormalities were categorized according to the
binary metabolic syndrome (≥3 metabolic abnormalities, yes
or no) to allow for direct comparisons between prior studies
and our findings for white women and, afterward, to compare
our results across races and ethnicities. Second, metabolic
abnormalities were categorized as accumulated numbers of
metabolic abnormalities to further explore our findings. Given
that almost all overweight (79%) and obese (98%) women had
a waist circumference ≥80 cm, groups with 0 or 1 metabolic
abnormality were combined for overweight and obese women
(leaving 4 categories: 0 to 1, 2, 3, or ≥4 metabolic
abnormalities). To enable comparison with primary analyses,
the reference category comprised normal weight women with
≤2 metabolic abnormalities (without the metabolic syndrome).
Third, we assessed the associations between the most
frequent combinations of the metabolic syndrome compo-
nents and cardiovascular risk (no metabolic abnormalities as
the reference category) to explore whether specific combina-
tions of abnormalities drove our results. Due to few events in
Hispanic women, we conducted analyses according to
combinations of metabolic abnormalities only in white and
black women. The first 2 approaches were categorized based
on metabolic abnormalities and BMI category. The categories
in the third approach were independent of BMI category but
adjusted for BMI and waist circumference. All categories were
nominal; no ordering was assumed.
In each approach, we adjusted for age, smoking, and
hormone use at baseline in primary analyses. All models
were stratified by hormone therapy trial study arm and
hysterectomy status because stratification allowed us to
control for potential confounding. In separate models, we
also adjusted for physical activity, education, parity (number
of term pregnancies), and low-density lipoprotein cholesterol
(LDL-C) and treatment with lipid-lowering drugs. Overall
incidence rates per 1000 person-years for each race or
ethnicity were age standardized to 1998 US population data
using the Surveillance, Epidemiology, and End Results (SEER)
program. The proportional hazards assumption was assessed
by visual examination of Schoenfeld residual plots, which
appeared to be satisfied unless otherwise indicated. To
explore whether associations between obesity and metabolic
health subtypes and cardiovascular risk differed according to
race or ethnicity, we tested for effect modification through
the use of statistical interaction terms in the metabolic
syndrome model, but not in the models with metabolic
health defined by number of metabolic abnormalities or
combination of metabolic syndrome components due to lack
of statistical power. Furthermore, we included only white and
black women because of the small number of Hispanic
women; we tested whether the associations between
metabolic health status and cardiovascular risk within each
BMI category differed between white and black women by
use of pair-wise comparison tests.
In sensitivity analyses we included women with diabetes at
baseline. In additional sensitivity analyses, we used the higher
threshold for impaired fasting glucose of 110 mg/dL (6.1
mmol/L) used by European guidelines18 and the World Health
Organization because several studies have found no incre-
mental risk with a threshold of 100 mg/dL.19,20 We also
conducted a sensitivity analysis in which all women receiving
hormone therapy at baseline or in the active intervention arm
of the hormone therapy trials were excluded. Moreover, we
evaluated a different definition of metabolically unhealthy
Figure 1. Flowchart of study. *Cardiac arrest, heart failure,
cardiac catheterization, atrial fibrillation, aortic aneurism,
angioplasty of coronary arteries, coronary bypass surgery, or
other heart problems. BMI indicates body mass index; EA HT,
European American Hormone Trial subcohort; SHARe, SNP
Health Association Resource cohort.
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Table 1. Baseline Characteristics of the Analytic Cohort of Postmenopausal Women According to BMI Categories (n=14 364)
Normal Weight (BMI 18.5 to <25) Overweight (BMI 25 to <30) Obese (BMI ≥30)
n=3625 n=5335 n=5404
Age, y
50 to 59 28 31 37
60 to 69 42 45 45
70 to 79 30 24 18
Race/ethnicity
Non-Hispanic white 56 46 42
Black or African American 25 35 43
Hispanic/Latino 19 19 15
Waist circumference
≥80 cm 23 79 98
≥88 cm 4 36 88
High glucose (≥100 mg/dL) 14 22 34
Glucose (mg/dL), mean (SD) 90.3 (9.4) 92.9 (9.9) 96.3 (10.9)
High measured blood pressure* (SBP ≥130 and/or DBP ≥85) 41 49 56
Hypertension*
Never hypertensive 77 66 55
Untreated hypertensive 6 9 9
Treated hypertensive 17 25 35
High triglycerides (≥150 mg/dL) 18 31 34
Low HDL-C (≤50 mg/dL) 23 38 48
Insulin resistance† 25 42 49
LDL-C‡ (mg/dL), median (IQR) 142 (120 to 168) 149 (125 to 174) 148 (125 to 174)
Lipid-lowering drugs‡ 10 14 12
Smoking
Never 52 53 53
Former 35 38 40
Current 13 9 7
Total minutes of physical activity, hours/week
<1 24 30 43
1 to 2 15 17 17
2 to 3.5 19 20 17
≥3.5 41 33 23
Hormone use
Never 58 58 62
Past 21 20 19
Current 21 21 19
HRT arm and hysterectomy status
Not randomized to HRT plus no hysterectomy 19 20 20
Not randomized to HRT plus hysterectomy 17 21 23
E-alone intervention 10 11 13
E-alone control 9 12 13
Continued
DOI: 10.1161/JAHA.114.001695 Journal of the American Heart Association 4
Race/Ethnicity, BMI, Metabolism, and CVD Risk Schmiegelow et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
obese, that is, by being obese, defined as a BMI ≥30 or waist
circumference ≥80 cm, in addition to at least 2 other
metabolic syndrome components.9 In the latter analyses,
normal weight and overweight women with a waist circum-
ference <80 cm but ≥2 metabolic abnormalities were
considered metabolically unhealthy, albeit not obese, and
categorized separately. Finally, we explored the associations
between presence of the metabolic syndrome and CVD risk
according to BMI as a continuous variable using normal
weight, metabolically healthy women as reference.
Analyses were performed with SAS software, version 9.3
(SAS Institute, Inc), and R 3.0 (R Foundation for Statistical
Computing).
Results
Of 22 128 women with biomarker data, 7438 met exclusion
criteria and 326 had missing data on covariates, yielding a final
analytic cohort of 14 364 women (Figure 1). The median age of
the study population was 64 years (interquartile range 57 to 69
Table 1. Continued
Normal Weight (BMI 18.5 to <25) Overweight (BMI 25 to <30) Obese (BMI ≥30)
n=3625 n=5335 n=5404
E+P intervention 22 18 16
E+P control 22 18 15
US region
Northeast 22 20 20
South 31 34 36
Midwest 21 21 24
West 26 25 21
Education‡
Did not go to school 0 0 0
Grade school (1 to 4 years) 1 1 1
Grade school (5 to 8 years) 1 2 2
Some high school (9 to 11 years) 4 5 6
High school diploma or GED 17 17 19
Vocational or training school 11 12 13
Some college or associate degree 26 27 28
College degree or bachelor degree 10 9 8
Some postgraduate or professional 10 9 8
Master degree 16 14 12
Doctoral degree 2 2 2
Number of term pregnancies‡
Never pregnant 9 7 7
Never had term pregnancy 4 3 4
1 11 10 10
2 23 22 21
3 22 23 21
4 16 16 16
≥5 14 18 21
Data are shown as percentages, except as noted. BMI indicates body mass index; DBP, diastolic blood pressure; E+P, estrogen plus progestin; E-alone, estrogen alone; GED, General
Educational Development; HDL-C, high-density lipoprotein cholesterol; HRT, hormone replacement therapy; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; SBP,
systolic blood pressure.
*In the models, high blood pressure comprised high measured blood pressure and treated hypertension.
†Triglycerides/HDL-C >2.47 (75th percentile among healthy-weight women).
‡Variables with missing data: LDL-C (n=118), lipid-lowering drugs (n=5), education (n=122), and number of term pregnancies (n=92).
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Table 2. Baseline Characteristics of the Analytic Cohort of Postmenopausal Women According to Race or Ethnicity (n=14 364)
White Black Hispanic
n=6741 n=5102 n=2521
Age, y
50 to 59 15 45 53
60 to 69 48 42 39
70 to 79 37 13 9
BMI category
Normal weight (18.5 to <25) 30 18 27
Overweight (25 to <30) 37 36 41
Obese (≥30) 33 46 32
Waist circumference
≥80 cm 71 77 66
≥88 cm 48 52 38
High glucose (≥100 mg/dL) 27 23 22
Glucose (mg/dL), mean (SD) 95 (10) 93 (11) 92 (10)
High blood pressure (SBP ≥130 and/or DBP ≥85) 50 55 38
Hypertension
Never hypertensive 70 52 76
Untreated hypertensive 8 9 8
Treated hypertensive 22 38 16
High triglycerides (≥150 mg/dL) 35 15 40
Low HDL-C (≤50 mg/dL) 42 31 43
Insulin resistance* 47 26 52
LDL-C† (mg/dL), median (IQR) 152 (130 to 176) 143 (119 to 171) 141 (119 to 165)
Lipid-lowering drugs† 12 12 12
Smoking
Never 51 49 63
Former 40 39 30
Current 9 12 6
Total minutes of physical activity, hours/week
<1 30 37 35
1 to 2 17 16 16
2 to 3.5 19 18 18
≥3.5 34 28 31
Hormone use
Never 66 57 47
Past 26 15 14
Current 8 28 38
HRT arm and hysterectomy status
Not randomized to HRT plus no hysterectomy 0 36 41
Not randomized to HRT plus hysterectomy 0 42 32
E-alone intervention 18 6 5
E-alone control 18 7 6
Continued
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years), and 47% were white, 36% were black, and 18% were
Hispanic. As BMI increased, all components of the metabolic
syndrome became more common, as did clustering of meta-
bolic abnormalities (Table 1). Elevated blood pressure was
more common in black women, but untreated hypertension
was uncommon in all race and ethnicity categories (Table 2).
High triglycerides and low HDL-C were more common in white
and Hispanic women than in black women (Table 2). Over a
median follow-up of 13 years (interquartile range 12 to
14 years), 1101 women (7.7%) had a first cardiovascular event
(718 coronary heart disease, 411 ischemic stroke, 48 both
events), for an incidence rate of 6.4 per 1000 person-years.
Race- or ethnicity-specific incidence rates of CVD were 8.8 per
1000 person-years (95% confidence interval [CI] 8.1 to 9.6 per
1000 person-years) for white women, 4.8 per 1000 person-
years (CI 4.2 to 5.5 per 1000 person-years) for black women,
and 3.2 per 1000 person-years (CI 2.5 to 4.2 per 1000 person-
years) for Hispanic women.
Metabolically Healthy Defined by the Metabolic
Syndrome
Women who were metabolically unhealthy (based on the
standard binary definition of metabolic syndrome) had
Table 2. Continued
White Black Hispanic
n=6741 n=5102 n=2521
E+P intervention 33 5 9
E+P control 31 5 8
US region
Northeast 25 17 12
South 20 49 42
Midwest 28 23 4
West 27 11 42
Education†
Did not go to school 0 0 0
Grade school (1 to 4 years) 0 0 4
Grade school (5 to 8 years) 1 1 7
Some high school (9 to 11 years) 4 6 8
High school diploma or GED 22 13 17
Vocational or training school 12 12 12
Some college or associate degree 29 26 25
College degree or bachelor degree 9 9 7
Some postgraduate or professional 0 9 6
Master degree 11 19 9
Doctoral degree 2 2 2
Number of term pregnancies†
Never pregnant 7 7 9
Never had term pregnancy 2 6 3
1 7 16 9
2 20 25 22
3 25 18 21
4 18 12 16
≥5 20 15 19
Data are shown as percentages, except as noted. BMI indicates body mass index; DBP, diastolic blood pressure; E+P, estrogen plus progestin; E-alone, estrogen alone; HDL-C, high-density
lipoprotein cholesterol; HRT, hormone replacement therapy; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
*Triglycerides/HDL-C >2.47 (75th percentile among healthy-weight women.
†Variables with missing data: LDL-C (n=118), lipid-lowering drugs (n=5), education (n=122), and number of term pregnancies (n=92).
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increased CVD risk regardless of BMI category in all racial and
ethnic groups (Figure 2), although there were too few events
among the Hispanic women for precise estimates. White
women who were overweight or obese but metabolically
healthy had a cardiovascular risk that was not statistically
different from normal weight metabolically healthy women
(Figure 2A). Metabolically healthy obese black women,
however, had a significantly increased cardiovascular risk,
and overweight metabolically healthy black women showed
a trend toward increased cardiovascular risk compared with
normal weight metabolically healthy women (Figure 2B). The
associations between metabolic health status and cardio-
vascular risk differed significantly between white and black
women; statistically significant interactions were found
between BMI categories and race or ethnicity (white or
black) within metabolic health categories (Figure 2). Among
the metabolically healthy women, overweight black women
had higher cardiovascular risk than overweight white women
(interaction P=0.05), and obese black women had higher
cardiovascular risk than obese white women (interaction
P=0.02). Among the metabolically unhealthy women, normal
weight black women had higher cardiovascular risk than
normal weight white women (interaction P=0.01), overweight
black women had a trend toward higher cardiovascular risk
than overweight white women (interaction P=0.18), and
obese black women had higher cardiovascular risk than
obese white women (interaction P=0.04).
Metabolically Healthy Defined by Number of
Metabolic Disorders
We found a graded association between increasing number of
metabolic abnormalities and increased cardiovascular risk in
each BMI category in both white and black women (Figure 3A
and 3B). Furthermore, black women with just 2 metabolic
abnormalities who were overweight or obese had increased
risk of CVD (Figure 3B), even though they would be consid-
ered metabolically healthy based on the standard binary
A White women
HR (CI) Events, no./total
1.51 (1.22−1.86)
1.07 (0.80−1.42)
1.41 (1.13−1.76)
0.92 (0.72−1.17)
2.13 (1.60−2.85)
(ref)
193/1514
66/737
151/1106
114/1364
64/313
167/1707
Obese
Overweight
Normal weight
Metabolically healthy
Metabolically unhealthy
Obese
Overweight
Normal weight
B Black women
2.49 (1.59−3.92)
1.95 (1.23−3.08)
2.03 (1.23−3.34)
1.49 (0.93−2.39)
5.61 (2.91−10.78)
(ref)
72/1100
63/1239
38/581
54/1259
14/92
26/831
Obese
Overweight
Normal weight
Metabolically healthy
Metabolically unhealthy
Obese
Overweight
Normal weight
1.67 (0.84−3.35)
1.00 (0.41−2.45)
1.33 (0.65−2.71)
1.05 (0.52−2.14)
3.08 (1.29−7.37)
(ref)
18/504
7/310
15/427
15/598
8/91
16/591
Obese
Overweight
Normal weight
Metabolically healthy
Metabolically unhealthy
Obese
Overweight
Normal weight
0.5 1.0 2.0 3.0 5.0 10.0 15.0
C Hispanic women
Figure 2. Hazard ratios of the composite outcome of coronary heart disease and ischemic stroke by BMI
categories and the presence of the metabolic syndrome in (A) white women, (B) black women, and (C)
Hispanic women. Healthy-weight women with <3 (0, 1, or 2) metabolic abnormalities were used as the
reference in all models; models were adjusted for age, smoking, and hormone use at baseline and stratified
by hormone therapy trial study arm and hysterectomy status. BMI indicates body mass index; HR, hazard
ratio; ref, reference.
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definition of metabolic syndrome (Figure 1), especially
because 1 of these abnormalities was abdominal obesity for
79% of overweight women and 98% of obese women. In
contrast, white obese women with 3 metabolic abnormalities
did not have a statistically significantly increased cardiovas-
cular risk (Figure 3A), although the standard binary definition
of metabolic syndrome would categorize them as metaboli-
cally unhealthy. The number of Hispanic women in each
category was too small to permit precise risk estimates
(Figure 3C).
1.84 (1.47−2.32)
1.02 (0.75−1.40)
1.06 (0.76−1.47)
1.07 (0.67−1.71)
1.71 (1.32−2.22)
1.15 (0.86−1.53)
0.98 (0.74−1.30)
0.83 (0.59−1.16)
2.81 (1.85−4.26)
1.84 (1.29−2.62)
(ref)
139/879
54/635
46/521
20/216
86/511
65/595
71/759
43/605
26/103
38/210
167/1707
≥4 
≥4
3 
3
2
Obese
Overweight
Normal weight
HR (CI)
A White women
2.81 (1.65−4.81)
2.33 (1.43−3.81)
2.17 (1.35−3.48)
1.30 (0.64−2.65)
2.14 (1.11−4.12)
1.97 (1.13−3.44)
1.77 (1.07−2.92)
1.10 (0.59−2.05)
9.65 (3.67−25.36)
4.57 (2.13−9.80)
(ref)
29/401
43/699
52/909
11/330
14/207
24/374
38/705
16/554
5/24
9/68
26/831
B Black women
1.22 (0.47−3.18)
2.06 (0.96−4.42)
0.64 (0.18−2.20)
1.74 (0.58−5.26)
1.92 (0.84−4.37)
0.91 (0.35−2.34)
1.61 (0.74−3.50)
0.54 (0.18−1.62)
2.34 (0.52−10.50)
3.41 (1.31−8.88)
(ref)
6/217
12/287
3/200
4/110
9/178
6/249
11/294
4/304
2/28
6/63
16/591
0.5 1.0 2.0 3.0 5.0 10.0 15.0
C Hispanic women
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Figure 3. Hazard ratios of the composite outcome of coronary heart disease and ischemic stroke by
BMI categories in (A) white women, (B) black women, and (C) Hispanic women, according to
incremental number of metabolic abnormalities. Normal weight women with <3 (0, 1, or 2) metabolic
abnormalities were used as the reference in all models; models were adjusted for age, smoking, and
hormone use at baseline and stratified by hormone therapy trial study arm and hysterectomy status.
#abnl indicates number of metabolic abnormalities; BMI, body mass index; HR, hazard ratio; ref,
reference.
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Cardiovascular Risk According to Combination of
Metabolic Abnormalities
We assessed whether specific combinations of risk factors
conveyed greater degrees of cardiovascular risk by combining
all white women (Figure 4A) and black women (Figure 4B)
and applying a model that adjusted for BMI and waist
circumference. There was no strong evidence that any
particular combination of 2 (or 3) factors conveyed
substantially different risk than any other combination
(Figure 4). Furthermore, although the sample sizes were
small in the racial and ethnic subgroups, elevated blood
pressure did not appear to be associated with a different
CVD risk for black women compared with for white women
(interaction P=0.90).
Sensitivity Analyses
The main findings of this study were not changed when
women with diabetes at baseline were included and catego-
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Figure 4. Hazard ratios of the composite outcome of coronary heart disease and ischemic stroke
according to BMI categories and specific combinations of metabolic abnormalities in (A) white women and
(B) black women. Women with no metabolic abnormalities were used as the reference in all models, and all
models were adjusted for age, smoking, BMI, waist circumference, and hormone use at baseline and
stratified by hormone therapy trial study arm and hysterectomy status. BMI indicates body mass index; BP,
blood pressure; HDL-C, high density lipoprotein-cholesterol; HR, hazard ratio; ref, reference; TG,
triglycerides.
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rized as fulfilling the criterion for impaired fasting glucose (ie,
glucose ≥100 mg/dL) (Table 3) or when we used the higher
threshold for impaired fasting glucose of 110 mg/dL in the
primary study cohort (Table 4). Following exclusion of all
women receiving hormone therapy at baseline, the population
for these sensitivity analyses comprised 3057 white women,
Table 3. HRs of Cardiovascular Disease According to Body Mass Index and Metabolic Health Including Women With Diabetes*
White Black Hispanic
n=7508 n=6043 n=2802
Metabolic Abnormalities HR CI HR CI HR CI
Normal weight
0 to 2 Ref — Ref — Ref —
3 1.96 1.41 to 2.73 3.60 1.76 to 7.36 2.62 1.02 to 6.68
≥4 2.57 1.76 to 3.75 6.51 2.98 to 14.21 3.30 1.09 to 9.98
Overweight
0 to 1 0.79 0.57 to 1.11 0.99 0.55 to 1.79 0.48 0.16 to 1.42
2 0.99 0.76 to 1.30 1.59 0.99 to 2.54 1.34 0.63 to 2.85
3 1.15 0.87 to 1.51 1.81 1.10 to 2.98 0.83 0.35 to 2.01
≥4 1.89 1.49 to 2.37 3.29 2.03 to 5.31 2.30 1.15 to 4.58
Obese
0 to 1 1.02 0.64 to 1.63 1.18 0.60 to 2.32 1.51 0.51 to 4.49
2 1.05 0.77 to 1.44 1.84 1.18 to 2.88 0.68 0.23 to 2.04
3 1.12 0.85 to 1.49 2.69 1.77 to 4.08 2.07 1.04 to 4.11
≥4 1.96 1.60 to 2.40 3.21 2.09 to 4.91 1.53 0.74 to 3.20
All models were adjusted for age, smoking, and hormone use at baseline and stratified by hormone therapy trial study arm and hysterectomy status. HR indicates hazard ratio.
*Women with diabetes were categorized as having an abnormal glucose metabolism regardless of fasting glucose levels.
Table 4. HRs of Cardiovascular Disease According to Body Mass Index and Metabolic Health Defining Impaired Glucose
Metabolism as Fasting Glucose ≥110 mg/dL in a Cohort of Postmenopausal Women
White Black Hispanic
n=6741 n=5102 n=2521
Metabolic Abnormalities HR CI HR CI HR CI
Normal weight
0 to 2 Ref — Ref — Ref —
3 1.75 1.18 to 2.59 2.81 1.09 to 7.29 3.11 1.14 to 8.54
≥4 3.02 1.97 to 4.64 11.02 4.23 to 28.69 1.47 0.19 to 11.22
Overweight
0 to 1 0.72 0.52 to 1.00 0.96 0.53 to 1.72 0.76 0.32 to 1.84
2 1.07 0.82 to 1.38 1.61 1.00 to 2.59 1.18 0.53 to 1.81
3 1.17 0.88 to 1.55 2.11 1.25 to 3.58 0.96 0.40 to 2.32
≥4 1.76 1.33 to 2.33 1.29 0.57 to 2.95 1.81 0.75 to 4.37
Obese
0 to 1 0.87 0.55 to 1.37 1.18 0.61 to 2.28 2.02 0.79 to 5.15
2 1.05 0.77 to 1.42 1.73 1.11 to 2.71 0.53 0.16 to 1.81
3 1.24 0.94 to 1.64 2.56 1.61 to 4.07 1.45 0.66 to 3.12
≥4 1.84 1.45 to 2.35 2.47 1.39 to 4.37 1.50 0.58 to 3.84
All models were adjusted for age, smoking, and hormone use at baseline and stratified by hormone therapy trial study arm and hysterectomy status. HR indicates hazard ratio.
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3217 black women, and 1243 Hispanic women. Although
limited by few events, particularly among nonwhite partici-
pants, the hazard ratios did not change considerably, leaving
our main findings unaltered. Furthermore, our results were
unchanged when we defined metabolically unhealthy as being
obese (waist circumference ≥80 cm or BMI ≥30) in addition
Table 5. HRs of Cardiovascular Disease in a Cohort of Postmenopausal Women According to BMI and Metabolic Health Using a
Different Categorization*
White Black Hispanic
n=6741 n=5102 n=2521
Binary Model HR CI HR CI HR CI
Metabolically healthy*
Normal weight Ref — Ref — Ref —
Overweight 1.05 0.81 to 1.37 1.54 0.95 to 2.52 1.30 0.60 to 2.78
Obese 1.25 0.92 to 1.69 1.85 1.15 to 3.00 1.13 0.44 to 2.91
Metabolically unhealthy†
Normal weight, WC <80 cm 2.09 1.54 to 2.82 1.24 0.50 to 3.05 3.17 1.32 to 7.61
Normal weight, WC ≥80 cm‡ 2.60 1.84 to 3.67 6.18 3.00 to 12.73 2.05 0.56 to 7.44
Overweight, WC <80 cm 1.18 0.65 to 2.14 0.88 0.26 to 2.95 1.69 0.47 to 6.03
Overweight, WC ≥80 cm‡ 1.66 1.31 to 2.12 1.88 1.11 to 3.19 1.32 0.59 to 2.96
Obese‡ 1.74 1.38 to 2.20 2.46 1.53 to 3.94 1.88 0.89 to 3.98
BMI indicates body mass index; HR, hazard ratio; WC, waist circumference.
*Metabolically healthy defined as having <2 metabolic abnormalities.
†Metabolically unhealthy defined as having ≥2 metabolic abnormalities.
‡Metabolically unhealthy obese: obese (WC ≥80 cm or BMI ≥30) and ≥2 additional metabolic abnormalities.
Table 6. HRs of Cardiovascular Disease in a Cohort of Postmenopausal Women According to BMI and Metabolic Health Using a
Different Categorization*
White Black Hispanic
n=6741 n=5102 n=2521
Numeric Model HR CI HR CI HR CI
Normal weight
0 to 1 Ref — Ref — Ref —
2 2.02 1.49 to 2.73 1.72 0.79 to 3.73 1.80 0.63 to 5.18
≥3 2.79 1.98 to 3.95 6.09 2.71 to 13.69 4.72 1.81 to 12.28
Overweight
0 0.84 0.56 to 1.27 1.07 0.51 to 2.26 0.47 0.11 to 2.12
1 1.15 0.87 to 1.54 1.72 1.04 to 2.86 1.77 0.80 to 3.90
2 1.33 0.99 to 1.79 1.51 0.84 to 2.72 0.50 0.14 to 1.79
≥3 1.95 1.48 to 2.56 2.15 1.13 to 4.09 2.48 1.11 to 5.58
Obese
0 1.27 0.78 to 2.06 1.33 0.65 to 2.75 2.09 0.67 to 6.52
1 1.24 0.88 to 1.74 2.02 1.23 to 3.32 0.71 0.20 to 2.54
2 1.16 0.83 to 1.60 2.29 1.38 to 3.82 2.32 1.03 to 5.25
≥3 2.15 1.68 to 2.75 2.68 1.54 to 4.67 1.37 0.50 to 3.72
BMI indicates body mass index; HR, hazard ratio.
*Waist circumference not included, and the reference category was defined as <2 metabolic abnormalities to make the models comparable; metabolically healthy obese was defined as
being obese (waist circumference ≥80 cm or BMI ≥30) and having <2 additional metabolic abnormalities.
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to having at least 2 metabolic abnormalities (Tables 5 and 6).
Analyses examining associations between the metabolic
syndrome and CVD risk, treating BMI as continuous,
confirmed our findings that the metabolically healthy obese
concept applied to white women but not to all races and
ethnicities (Figure 5). Finally, self-reported physical activity,
education, parity, and LDL-C and lipid-lowering drugs did not
change any of the estimates considerably (data not shown).
Discussion
In this prospective study of postmenopausal women without
diabetes or prior CVD, the risk of developing CVD was more
strongly associated with the presence of metabolic abnormal-
ities than with the presence of obesity, regardless of racial or
ethnic background. Furthermore, metabolic abnormalities
appeared to confer more cardiovascular risk among black
women than among white women. Almost all prior studies of
obesity, metabolic health, and cardiovascular risk have been
limited to white participants and have relied on the presence or
absence of metabolic syndrome to define metabolic
health.5,9,16 Our finding that obesity in white women was not
associated with increased cardiovascular risk unless accom-
panied by the metabolic syndrome confirms the results of
other studies.8,9 Our most novel finding was that black women
who were overweight or obese had elevated cardiovascular
risk even when they did not have the metabolic syndrome. It
appeared that the cardiovascular risk was elevated in black
women by the presence of only 2 or 3 metabolic abnormalities
to a degree that would require ≥4 metabolic abnormalities
among white women (Figure 2). The metabolic syndrome itself
has already been evaluated extensively and found to be no
greater than the sum of its parts.21,22 This study further
suggests that the use of the “metabolic syndrome” to define
the metabolically healthy obese group appears to underesti-
mate risk among black women and to overestimate cardio-
vascular risk in white women. Instead, an individualized
approach in which the clinician considers the sum and the
type of metabolic syndrome components in light of the
patient’s overall risk profile should be encouraged, especially
when applied to populations other than white.
It has been controversial whether metabolically healthy
obesity is a valid concept, and our study suggests that this
concept may not apply to black women. A recent meta-
analysis and systematic review found that the lower cardio-
vascular risk in metabolically healthy obese persons was
documented only in studies that had limited follow-up
(<10 years of follow-up).16 The findings, however, were
unadjusted and also might have been limited by ecological
bias. Obesity has been found to be associated with long-term
cardiovascular risk,23 and long-standing obesity has been
somewhat more strongly associated with cardiovascular
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Figure 5. Hazard ratios of the composite out-
come of coronary heart disease and ischemic
stroke according to presence of the metabolic
syndrome by increasing body mass index (BMI) in
(A) white women, (B) black women, and (C)
Hispanic women. Healthy-weight women with <3
(0, 1, or 2) metabolic abnormalities were used as
the reference in all models; models were adjusted
for age, smoking, and hormone use at baseline
and stratified by hormone therapy trial study arm
and hysterectomy status. The shaded regions
around the lines gives the 95% confidence band,
the standard error, for the mean. *Please note
that the scale of the y-axis differs for white (0 to
3), black (0 to 10), and Hispanic (0 to 80) women,
so the widths of the CIs are not comparable.
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risk.24 The Norwegian HUNT study found that being obese but
metabolically healthy was not associated with increased risk
of myocardial infarction but with increased risk of heart
failure,9 whereas a study of younger persons found that the
composite cardiovascular risk (myocardial infarction, stroke,
coronary revascularization) of the metabolically healthy obese
group was comparable to normal weight metabolically healthy
persons only in analyses adjusted for fitness.5 In our study,
adjustment for the level of physical activity did not change the
results, perhaps because the WHI population was older and
female. Furthermore, in a recent Korean cross-sectional
study, being metabolically healthy obese (obese without any
metabolic syndrome components and homeostasis model
assessment for insulin resistance <2.5) was associated with
subclinical coronary atherosclerosis but not after adjustment
for lipids (LDL-C, HDL-C, and triglycerides), systolic blood
pressure, homeostasis model assessment for insulin resis-
tance, and glucose.25 These findings suggest that obesity is
not a harmless condition because it is closely correlated with
increased risk of insulin resistance and risk of developing
metabolic abnormalities.26 Indeed, a recently published study
found that after 5 years of follow-up, 31.8% of metabolically
healthy obese individuals (defined as BMI ≥30 and ≤1
metabolic syndrome component, 75% men) had become
metabolically unhealthy, rising to 51.5% after 20 years.27 In
the absence of metabolic syndrome, obesity might still be
associated with increased metabolic risk among black women
and thus the need for lifestyle intervention as a “window of
opportunity.” Our findings underscore the importance of
preventing the development of metabolic disorders, particu-
larly in black overweight and obese women, in whom
metabolic disorders were more strongly associated with
increased cardiovascular risk than in white women.
Strengths and Limitations
This large study is unique in having more black participants
than other studies and thus could evaluate racial and ethnic
differences in the risk of CVD according to obesity and
metabolic health status. Its other strengths include the use of
prospectively collected data with coronary heart disease and
ischemic stroke as adjudicated end points, the long follow-up,
and the available fasting measures of glucose and lipid levels
for 15 000 postmenopausal women without CVD or diabe-
tes.
This study also had several limitations. First, the WHI
enrolled only postmenopausal women, so our results may not
be generalizable either to younger women or to men. Second,
the definition of metabolically healthy obese varies among
studies,16 although most use either the ATP III8 or the
International Diabetes Federation criteria for the metabolic
syndrome.5,9 Without a uniform definition of metabolically
healthy obese, it is difficult to compare studies.28 We used the
most commonly applied definition, and our findings were
unchanged when we applied an alternative, also widely used
definition of metabolically healthy,9 namely, ≥2 metabolic
abnormalities in addition to obesity (defined as BMI ≥30 or a
waist circumference ≥80 cm). Third, menopausal hormone
therapy increases HDL-C and triglycerides, which should be
taken into account when interpreting the results. Neverthe-
less, changes induced by hormone therapy were not associ-
ated with future risk of coronary heart disease in a WHI
study.29 Fourth, the number of Hispanic women was limited,
so we could not include an interaction term between race, and
the obesity and metabolic abnormality categories in the
model with metabolic health defined by number of metabolic
abnormalities. Instead, we reported the estimates of risk by
race or ethnicity and noted differences that were consistent
with our hypothesis and that should be formally tested in
future studies designed to have adequate statistical power.
The uncertainty surrounding the estimates in the Hispanic
women was greater because of the relatively small number of
Hispanic women in the cohort. Finally, muscle tissue
composes a smaller proportion of overall body mass in
postmenopausal women, thus BMI may be lower in these
women despite higher fat mass.
In conclusion, in postmenopausal women without diabetes
or prior CVD, the presence of even a few metabolic
abnormalities was more strongly associated with increased
cardiovascular risk in black overweight and black obese
women than in white women. Women with ≤1 metabolic
abnormality who were overweight or obese did not appear to
have increased risk of CVD regardless of race or ethnicity.
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